US 11,672,802 B2
Induction of immune tolerance by using methotrexate
Alexandra Joseph, Lexington, MA (US); Susan Richards, Sudbury, MA (US); Melanie Ruzek, Acton, MA (US); and Richard Garman, Natick, MA (US)
Assigned to Genzyme Corporation, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Mar. 24, 2020, as Appl. No. 16/828,407.
Application 16/828,407 is a continuation of application No. 14/116,486, abandoned, previously published as PCT/US2012/036405, filed on May 3, 2012.
Claims priority of provisional application 61/486,697, filed on May 16, 2011.
Prior Publication US 2020/0360385 A1, Nov. 19, 2020
Int. Cl. A61K 31/519 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 39/0008 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method of increasing the percentage of B regulatory cells in the B cell population in a subject in need of treatment with a therapeutic, comprising administering to the subject an effective amount of methotrexate, thereby increasing said percentage in said subject, wherein the subject is administered a therapeutic for more than one cycle of a dosing regimen, wherein the therapeutic is human acid alpha-glucosidase, wherein the effective amount of methotrexate is administered in a single cycle of the dosing regimen of the therapeutic, and wherein methotrexate is not administered in subsequent cycles of the dosing regimen of the therapeutic.